About PPA   |   Contact Us   |   Report Abuse   |   Sign In   |   Join Now
CE Webinar: Come Together Right Now: Connecting Lipid Guidelines with Novel Non-Statin Therapies
Tell a Friend About This EventTell a Friend
CE Webinar: Come Together Right Now: Connecting Lipid Guidelines with Novel Non-Statin Therapies

Join us for this convenient online CE webinar!

7/14/2016
When: Thursday, July 14, 2016
11 AM to 12:30 PM
Where: Webinar
Access instructions provided upon registration
United States
Presenter: Kimberly L. Carter, PharmD, BCACP, Assistant Professor, Jefferson College of Pharmacy
Contact: Sara Powers
(717) 234-6151 x. 2


Online registration is closed.
« Go to Upcoming Event List  

Title: Come Together Right Now: Connecting Lipid Guidelines with Novel Non-Statin Therapies

The release of the ACC/AHA Lipid Guidelines in 2013 changed clinical practice by moving away from LDL-C specific goals and emphasizing statin therapy for all at-risk patients.  With the recent FDA approval of PSCK9 inhibitors into the US pharmaceutical market, there is question as to where these extremely potent LDL-C reducing drugs fit into current guidelines. This program will discuss the evidence behind the use of PCSK9 inhibitors and other non-statin therapies in high-risk patients and debate where these agents fit into current practice.

 
Speaker:


Kimberly L. Carter, PharmD, BCACP, Assistant Professor, Jefferson College of Pharmacy

   

Target Audience: Primarily clinical pharmacists; however, all pharmacists may benefit as hyperlipidemia management is encountered in all areas of pharmacy practice

  
CE Credit: 1.5 Contact Hours (0.15 CEUs)

Program Objectives:
At the completion of this activity, the participant will be able to:
1. Review the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2. Compare and contrast current lipid guidelines with the ATP III guidelines; discuss existing controversies
3. Review the evidence regarding the use of non-statin therapies in high risk patients, including those with familial hypercholesteremia
4. Discuss the mechanism, dosing, efficacy, and safety of PSCK9 inhibitors
5. Debate where PSCK9 inhibitors and other non-statin therapies should fit into current lipid guidelines and apply learned concepts to patient cases
  
Schedule: 11:25 to 11:30 AM - Attendees log in
11:00 AM to 12:30 PM - CE Program
Activity Type: Application-based
Cost: PPA Members - Free
Non-Members - $20
   *Requests for cancellation refunds must be submitted to PPA at least one day in advance of the webinar. All refunds will be subject to a $5 administrative fee.
UAN: 0159-0000-15-078-L01-P
Requirements to receive credit: Participants must attend the entire program and complete an online evaluation survey within one week. PPA must have your CPE Monitor ID and birthday on file to issue credit. Individuals who received CE credit when this program was presented at PPA's
2016 Mid-year Conference may not receive CE credit a second time.

   

To Register:

Use the link above to register for this program. 


Click here to view current software requirements


The Pennsylvania Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Association Management Software Powered by YourMembership  ::  Legal